Sign in
Taking people in United StatesPhase 2

Tulisokibart for adults with active pulmonary sarcoidosis, compared with placebo

Tests tulisokibart against placebo in adults with active pulmonary sarcoidosis.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Shreveport, United StatesSee the site
Trial code
Registry title
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Status
Recruiting
Phase
Phase 2
People taking part
158 people, planned
Started
3 Nov 2026
Expected to end
11 Jan 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tulisokibart
  • Placebo
  • Background prednisone therapy
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active sarcoidosis of the lungs (pulmonary sarcoidosis). It tests tulisokibart against placebo, both given with prednisone.

Age
18 to 75 years
Sex
All sexes
Disease stage
Sarcoidosis diagnosed at least 6 months before screening and confirmed by tissue biopsy. Lung tissue involvement seen on chest X-ray or chest HRCT scan. Active pulmonary sarcoidosis within 3 months before screening.
Earlier treatment
People getting treatment for pulmonary hypertension (high blood pressure in the lungs) cannot join.

Main reasons for not taking part

  • Cancer in the past, with less than 5 years free of disease
  • Sarcoidosis of the heart, eyes, nerves or elsewhere that needs whole-body treatment, or a serious heart tracing (ECG) problem
  • Active tuberculosis now or in the past, or a fungal lung infection within 12 months without finished treatment
  • Löfgren syndrome
  • Smoking or vaping nicotine, tobacco or cannabis within 6 months before screening

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy
  • Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening
  • Has active PS within 3 months before Screening

Who cannot take part

  • Is receiving treatment for pulmonary hypertension
  • Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment
  • Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening
  • Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a clinically significant electrocardiogram abnormality that requires evaluation or intervention
  • Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome
  • Has active tuberculosis (TB) or history of active TB
  • Has any condition that may interfere with the ability to adhere to oral corticosteroid therapy or taper
  • Has a history of cancer and is disease free for <5 years
  • The main exclusion criteria include but are not limited to the following:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Care Access Research Llc (Site 2725)Shreveport, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).

Read full original descriptionShow less

This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.

The 2 groups in the trial

  • TulisokibartTreatment being tested

    Participants receive background therapy of prednisone plus tulisokibart.

    Treatment: Tulisokibart and Background prednisone therapy

  • PlaceboPlacebo, for comparison

    Participants receive background therapy of prednisone plus placebo.

    Treatment: Placebo and Background prednisone therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis
Plain-language title
Tulisokibart for adults with active pulmonary sarcoidosis, compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07867938, who can take part
Record updated
9 November 2026